TABLE 2.
PRRT Treatment Characteristics and Toxicities
| Age at the start of PRRT, median (range), y | 62 (37–74) |
| Years between NET diagnosis and initiation of PRRT, median (range), y | 3 (0–25) |
| PRRT sessions per patient, mean (range) | 2.5 (1–7) |
| Sessions per course of PRRT treatment, mean (range) | 2.2 (1–3) |
| Type of PRRT isotope, % | |
| 90Y | 34 |
| 177Lu | 25 |
| 90Y and 177Lu | 41 |
| Dose of PRRT given per session, median (range), mCi | |
| 90Y | 160 (120–200) |
| 177Lu | 200 (100–200) |
| Therapies administered prior to initiating PRRT, % | |
| Somatostatin analog therapy | 96 |
| Liver directed therapy | 79 |
| Non-hepatic surgery | 79 |
| Systemic chemotherapy | 39 |
| Number of different therapies prior to first PRRT, mean (range) | 2 (0–3) |
| Toxicities that developed during the first year after starting PRRT, % | |
| Anemia | 36 |
| Leukopenia | 31 |
| Thrombocytopenia | 24 |
| Nephrotoxicity | 27 |
| Biochemical liver injury (any) | 14 |
| Hyperbilirubinemia | 8 |
| Elevated AST | 12 |
| Elevated ALT | 7 |
AST indicates aspartate aminotransferase; ALT, alanine aminotransferase